Related Experiment Video

Updated: May 31, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Vascular homeostasis and angiogenesis determine therapeutic effectiveness in type 2 diabetes

Narisa Futrakul1, Prasit Futrakul

  • 1Renal Microvascular Research Group, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

International Journal of Vascular Medicine
|July 13, 2011
PubMed

Insights

Early type 2 diabetic nephropathy (DN) shows functional vascular homeostasis, unlike later stages. Vasodilator therapy in early DN (CKD stages 1-2) can improve kidney function by enhancing renal perfusion and correcting ischemia.

Area of Science:

  • Nephrology
  • Diabetology
  • Vascular Biology

Background:

  • Type 2 diabetic nephropathy (DN) is often diagnosed late (CKD stages 3-5) due to insensitive markers.
  • Late-stage DN exhibits defective angiogenesis, impaired nitric oxide (NO) production, and elevated anti-angiogenesis, leading to therapeutic resistance and progressive vascular disease.
  • Altered renal hemodynamics with reduced renal perfusion characterize advanced DN.

Purpose of the Study:

  • To investigate the state of vascular homeostasis in early versus late-stage type 2 diabetic nephropathy.
  • To determine the potential of vasodilator treatment in early-stage DN.

Main Methods:

  • Analysis of vascular homeostasis markers in different stages of diabetic nephropathy.
  • Evaluation of renal hemodynamics and perfusion.
  • Assessment of nitric oxide (NO) production and angiogenesis.

Main Results:

  • Vascular homeostasis is preserved in early-stage DN (CKD stages 1-2).
  • Late-stage DN shows impaired angiogenesis, reduced NO production, and increased anti-angiogenesis.
  • Vasodilator treatment in early DN enhances renal perfusion and corrects renal ischemia.

Conclusions:

  • Early detection and intervention in type 2 diabetic nephropathy are crucial.
  • Preserved vascular function in early DN allows for effective vasodilator therapy.
  • Targeting vascular homeostasis in early DN can restore renal function and prevent disease progression.

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...